RNAi Therapeutics News and Research

RSS

RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Silence Therapeutics plc announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases in a murine breast cancer metastasis model.

10 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2010, and company highlights.

4 Nov 2010

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded four Therapeutic Discovery Project (TDP) grants, totaling $977,917, by the United States Internal Revenue Service (IRS) as part of the Patient Protection and Affordable Care Act of 2010.

2 Nov 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

Silence Therapeutics plc announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the Zamore Design Rules.

20 Oct 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).

30 Sep 2010

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.

23 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.

24 Aug 2010

Preclinical studies of BIND-014 to be presented at ACS National Meeting

BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung.

23 Aug 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

MMV joins Pool for Open Innovation against neglected tropical diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).

17 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

RNAi Therapeutics News and Research

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Dicerna secures $4 million in second closing of Series B equity financing

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

Silence Therapeutics receives two patents for RNA interference therapeutics

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Preclinical studies of BIND-014 to be presented at ACS National Meeting

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

MMV joins Pool for Open Innovation against neglected tropical diseases

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Silence Therapeutics receives patent for RNA silencing method

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News